Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | GLS | O94925 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790333 | 0.95 | TDP1 (0.71) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL8863094 | 0.93 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| SCHEMBL8863154 | 0.93 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| SCHEMBL2604742 | 0.93 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| SCHEMBL6777483 | 0.93 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| SCHEMBL8862878 | 0.93 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| SCHEMBL8862728 | 0.93 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19CHRM2 | |
| SCHEMBL6699936 | 0.90 | GLS (0.71) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL766369 | 0.89 | TDP1 (0.59) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3433208 | 0.89 | TDP1 (0.59) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809368-B2 | Compounds affecting gap junction activity | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-08-19 | — | — | US | disclosed |
| US-20090143425-A1 | COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-06-04 | — | — | US | disclosed |
| US-20040176612-A1 | Method for preparing n-($g(v)-bromoalkyl)phthalimides | GILLET JEAN-PHILIPPE (FR) | 2004-09-09 | — | — | US | disclosed |
| US-20040176613-A1 | Method for preparing n-($g(v)-bromoalkyl)phthalimides | GILLET JEAN-PHILIPPE (FR) | 2004-09-09 | — | — | US | disclosed |
| US-RE35631-E | Method of production of essentially pure melatonin and the method of solubilizing melatonin in water | IFLO S.A.S. (IT) | 1997-10-14 | — | — | US | disclosed |
| EP-0330625-B1 | Total synthesis method for making an indole structure derivative product class, of the triptamine type, in particular, melatonin or N-acetyl-5-methoxytriptamine type, having a high purity degree and easily soluble, for therapeutic use against acquired immuno-deficiency syndromes | I F L O S A S DI GIORGIO E ALD (IT) | 1995-12-20 | — | — | EP | disclosed |
| US-5122535-A | Mixing with adenosine; treating AIDS | IFLO S.A.S. (IT) | 1992-06-16 | — | — | US | disclosed |
| EP-0330625-A2 | Total synthesis method for making an indole structure derivative product class, of the triptamine type, in particular, melatonin or N-acetyl-5-methoxytriptamine type, having a high purity degree and easily soluble, for therapeutic use against acquired immuno-deficiency syndromes | I.F.L.O. S.a.s. di Giorgio e Aldo Laguzzi (IT) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176612-A1 | Method for preparing n-($g(v)-bromoalkyl)phthalimides | GK, DGKA, GNG2 | TDP1 3482/4885L3MBTL1 3639/4885MAPT 1235/4885 |
| US-20090143425-A1 | COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY | GJB2, GJA1, GAP43 | TDP1 2312/4885L3MBTL1 4703/4885MAPT 2537/4885 |
| US-20040176613-A1 | Method for preparing n-($g(v)-bromoalkyl)phthalimides | GK, DGKG, DGKA | TDP1 3495/4885L3MBTL1 2675/4885MAPT 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.